Prednisolone Treatment in Acute Interstitial Nephritis

• Status: Recruiting
• Trial end date: 2027-09-01
• Target enrollment: 0
• Participant gender: All

Summary

A Prospective randomized trial with a primary objective to investigate the effect ofprdenisolone treatment in acute interstitial nephritis

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Region MidtJylland Denmark
• Collaborators: Aarhus University Hospital; Odense University Hospital
• Treatments: Prednisolone; Prednisone

Criteria

Inclusion Criteria:

• Biopsy verified AIN

• Clinical suspicion of AIN

• Age > 18 years

• One of following criteria:

• Plasma creatinine > 120 µmol/L or

• Plasma creatinine increase > 30 µmol/L or increase > 50 % of baseline plasma creatinine

• Fertile women are included

Exclusion Criteria:

• No ability to give informed consent

• Immunosuppressive treatment (including prednisolone) within 3 months before biopsy

• Autoimmune disease

• Prednisolone intolerance

• Pregnancy or lactation

• Active cancer (except basal cell carcinoma)

• Short life expectancy (< 6 months)

• CKD stage IV-V

• AIN secondary to or accompanied by glomerulonephritis, sarcoidosis or inherited interstitial renal disease

• Previous participation Withdrawal criteria

• Development of exclusion criterion

• Withdrawal of consent